Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 12:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 273 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: varenicline tartrate Clear all
Terminated No phase listed Observational Accepts healthy volunteers

Alternate Nicotine Delivery Systems and Airway Epithelial Biology

NCT01974063
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 15, 2026, 12:45 AM EDT
Recruiting Phase 3 Interventional

V+PSF-M for Tobacco Cessation in HIV Care in India

NCT05786547
View directory record Official record
Conditions
Human Immunodeficiency Virus, Smoking Cessation, Smoking, Tobacco
Interventions
Varenicline, Positively Smoke Free Mobile (PSF-M), Standard Care
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 15, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation

NCT03688802
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline) nasal spray, Placebo (vehicle control) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 15, 2026, 12:45 AM EDT
Recruiting Phase 2 Interventional

Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse

NCT06609369
View directory record Official record
Conditions
Tobacco Use, Tobacco Cessation, Insomnia
Interventions
Experimental health intervention, Varenicline
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 15, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

Varenicline for Methamphetamine Dependence

NCT01365819
View directory record Official record
Conditions
Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 15, 2026, 12:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations

NCT01156610
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Tobacco Treatment
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 15, 2026, 12:45 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Endothelial Function and Autonomic Regulation After Short-term Smoking Cessation: Varenicline Versus Placebo

NCT00673595
View directory record Official record
Conditions
Smoking
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 15, 2026, 12:45 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Treating Smokeless Tobacco Use in Rural Veterans

NCT02994082
View directory record Official record
Conditions
Smokeless Tobacco, Nicotine Dependence
Interventions
Tailored behavioral intervention, Behavioral activation for elevated depressive symptoms, Post-cessation weight gain management, Alcohol use risk reduction, Nicotine replacement therapy - transdermal nicotine patch, Nicotine replacement therapy - nicotine lozenge, Nicotine replacement therapy - nicotine gum, Bupropion sustained release, Varenicline, Combination nicotine replacement therapy, Combination nicotine replacement therapy + bupropion, Tobacco quit line, Educational materials
Behavioral · Drug
Lead sponsor
Mark Vander Weg
Federal
Eligibility
18 Years to 99 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 15, 2026, 12:45 AM EDT
Completed Not applicable Interventional Results available

Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers

NCT01714323
View directory record Official record
Conditions
Cigarette Smoking, Tobacco Smoking, Tobacco Use Disorder
Interventions
Sustained Care, Standard Care
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • Salem, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 15, 2026, 12:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Human Laboratory Study Of Varenicline in Smokers

NCT00709696
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Placebo, Varenicline
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Oct 15, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

Varenicline for Gait and Balance Impairment in Parkinson Disease

NCT01341080
View directory record Official record
Conditions
Parkinson Disease
Interventions
Varenicline, Sugar pill
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
40 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Oct 15, 2026, 12:45 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy

NCT04957758
View directory record Official record
Conditions
Neurotrophic Keratopathy
Interventions
OC-01 (varenicline) nasal spray 1.2 mg/ml, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
31
States / cities
Dothan, Alabama • Irvine, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 15, 2026, 12:45 AM EDT
Completed Phase 4 Interventional Results available

Varenicline for Nicotine Vaping Cessation in Adolescents

NCT05367492
View directory record Official record
Conditions
Vaping, Nicotine Dependence
Interventions
Double Blind Varenicline, Double Blind Placebo, QuitVaping, This Is Quitting
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 25 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 15, 2026, 12:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Precision Pharmacotherapy Smoking Cessation Program

NCT04897607
View directory record Official record
Conditions
Smoking Cessation
Interventions
Standard Care, Precision pharmacotherapy
Behavioral
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Mar 31, 2023 · Synced Oct 15, 2026, 12:45 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT03920215
View directory record Official record
Conditions
Long Term Follow up Dry Eye Disease
Interventions
OC-01 Low Dose, 0.12 mg/mL, OC-01 Mid Dose, 0.6 mg/mL, OC-01 High Dose, 1.2 mg/mL, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 15, 2026, 12:45 AM EDT
Completed Phase 2 Interventional

12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation

NCT00150228
View directory record Official record
Conditions
Smoking Cessation
Interventions
CP-526,555 (varenicline)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
7
States / cities
Lexington, Kentucky • Albert Lea, Minnesota • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2007 · Synced Oct 15, 2026, 12:45 AM EDT
Completed Not applicable Interventional Results available

My Mobile Advice Program: A Randomized Pilot Feasibility Study

NCT02136498
View directory record Official record
Conditions
Smoking Cessation, Medication Adherence
Interventions
Varenicline, Cognitive-behavioral self-help, MyMAP (My Mobile Advice Program)
Drug · Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 15, 2026, 12:45 AM EDT
Completed Phase 4 Interventional Results available

Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo

NCT00749944
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Oct 15, 2026, 12:45 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Reward Sensitivity and Pharmacotherapy for Smoking Cessation

NCT02162849
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Varenicline, Nicotine Patch, Placebo Patch, Placebo Tablet, Questionnaires, Counseling Sessions, Lab Session, Saliva Test
Drug · Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 15, 2026, 12:45 AM EDT
Completed Not applicable Interventional

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use

NCT04694846
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
Nicotine Replacement, Bupropion Hydrochloride Controlled-release, Varenicline, Tobacco Cessation Counseling, Questionnaire Administration, Quality of Life Assessment, Best Practice
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 15, 2026, 12:45 AM EDT
Completed Phase 4 Interventional

Smoking Study With Behavioral Therapy for Hypertensive Patients

NCT00879177
View directory record Official record
Conditions
Cigarette Smoking, Hypertension
Interventions
Varenicline, behavioral therapy
Drug · Behavioral
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 15, 2026, 12:45 AM EDT
Completed Phase 2 Interventional

Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment

NCT04634071
View directory record Official record
Conditions
Smoking Cessation, Cancer, Treatment-Related
Interventions
Varenicline, Bupropion, Long-acting nicotine replacement therapy, Low-intensity counseling, High-intensity counseling, No nicotine replacement therapy, Nicotine Replacement Products
Drug · Behavioral · Other
Lead sponsor
Joseph Valentino, MD
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Bowling Green, Kentucky • Lexington, Kentucky • Owensboro, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 15, 2026, 12:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study Investigating the Absorption and Elimination as Well as the Tolerability of Varenicline Transdermal Delivery System (e.g., a Patch) as Compared to Oral Varenicline in Adult Smokers.

NCT00661765
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline tartrate, varenicline free base
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2009 · Synced Oct 15, 2026, 12:45 AM EDT
Not listed Not applicable Interventional

Stage Ib Trial of mSMART for Smoking Cessation Medication Adherence

NCT02635919
View directory record Official record
Conditions
Nicotine Dependence
Interventions
mSMART
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 15, 2026, 12:45 AM EDT